GC
BMY.RT

Gruss & Co’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Gruss & Co’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-40,000
Closed -$90K – 33
2020
Q3 		$90K Buy
40,000
+15,000
+60% +$42.8K 0.02% 23
2020
Q2 		$88K Hold
25,000
– – 0.17% 31
2020
Q1 		$96K Buy
+25,000
New +$82.4K 0.18% 27

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BFS
Bard Financial Services Branford, Connecticut $911M AUM 19.14% 1-Year Est. Return
LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Gruss & Co's BMY.RT Position: Q4 2020 in Review

Gruss & Co sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 40,000 shares — an estimated $90K sold.

Gruss & Co first reported a position in BMY.RT in Q1 2020 and held it in 3 quarters. The position peaked at $96K in Q1 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

  • Gruss & Co reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
  • Gruss & Co sold 40,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $90K.
  • Gruss & Co first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 3 quarters.
  • Gruss & Co's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $96K in Q1 2020.
  • 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Gruss & Co's 13F filing for Q4 2020, filed 12 Feb 2021.